Hapoalim Securities Upgrades Amylin (AMLN) to Hold; Two Important Milestones Achieved
More News related to AMLN
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
- FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
- Hapoalim Securities Upgrades Amylin (AMLN) to Hold; Two Important Milestones Achieved
Hapoalim Securities upgrades Amylin (Nasdaq: AMLN) from Sell to Hold. Price target increased from $11 to $14.
Hapoalim analyst says, "Amylin Pharmaceuticals announced that the FDA has approved Byetta for use as monotherapy and, while the agency heightened the warning for pancreatitis, the FDA did not give the product a Black Box warning. Additionally, Amylin out-licensed its obesity program to Takeda (TKPHY, Not Covered) for $75 million up-front, which will help Amylin off-load some R&D costs...Our new target price of $14.00 is based on a sum-of-the-parts valuation, using our estimates for products, pipeline value, and shareholders' equity value as of September 30, 2009. We value Amylin at $2.1 billion based on this sum-of-the-parts model, or approximately $14.00 per diluted share."
To see more analyst ratings on AMLN Click Here.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.
Related Categories
UpgradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
